Anti-Coagulants - Switzerland

Switzerland

The Anti-Coagulants market in Switzerland is expected to witness a significant increase in revenue, reaching US$207.30m in 2024.
This growth is projected to continue with an annual growth rate (CAGR 2024-2029) of 7.41%, leading to a market volume of US$296.30m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue in this market, with a projected revenue of US$16,740.00m in 2024.
Switzerland, known for its advanced healthcare system, has seen a growing demand for novel oral anticoagulants among its population.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Switzerland has been experiencing steady growth in recent years.

Customer preferences: Swiss consumers are becoming increasingly health-conscious, leading to a rise in demand for preventative healthcare products like Anti-Coagulants. Additionally, the aging population in Switzerland has contributed to the growth of the Anti-Coagulants market, as older adults are more susceptible to blood clots and related health issues.

Trends in the market: One significant trend in the Anti-Coagulants market in Switzerland is the shift towards direct oral anticoagulants (DOACs) over traditional anticoagulants like warfarin. DOACs are more convenient for patients as they do not require frequent blood tests or dietary restrictions. Additionally, DOACs have been shown to have lower rates of major bleeding events compared to warfarin. Another trend in the Swiss Anti-Coagulants market is the increasing use of combination therapy, where patients are prescribed multiple Anti-Coagulants to achieve the desired therapeutic effect.

Local special circumstances: Switzerland has a highly developed healthcare system with a strong emphasis on research and innovation. This has led to the introduction of new Anti-Coagulants products and technologies in the market. Additionally, Switzerland is home to several large pharmaceutical companies that are major players in the Anti-Coagulants market.

Underlying macroeconomic factors: Switzerland has a high per capita income and a stable economy, which has contributed to the growth of the Anti-Coagulants market. Additionally, the Swiss government provides universal healthcare coverage, which has increased access to Anti-Coagulants for the general population. However, the high cost of Anti-Coagulants is a challenge for some Swiss consumers, leading to potential affordability issues.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.